What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

mTOR Signaling in Growth Control and Disease

Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,155

Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor

Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594

Wnt/β-Catenin Signaling in Development and Disease

Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568

mTOR: from growth signal integration to cancer, diabetes and ageing

Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941

Wnt signalling in stem cells and cancer

Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448

PI3K and cancer: lessons, challenges and opportunities

Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,762

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)

Ardito, F., Giuliani, M., PERRONE, D., Troiano, G., & Muzio, L. L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3036 · Cited by 1,437

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

An, Z., Aksoy, O., Zheng, T., Fan, Q.-W., & Weiss, W. A. (2018) · Oncogene · doi:10.1038/s41388-017-0045-7 · Cited by 708

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 602

Clinical management of breast cancer heterogeneity

Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 581

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer

Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290

Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0098 · Cited by 273

A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles

Rebecca, V. W., Nicastri, M. C., McLaughlin, N. P., Fennelly, C., Mcafee, Q. W., Ronghe, A. M., Nofal, M., Lim, C.-Y., Witze, E. S., Chude, C. I., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0741 · Cited by 213

Drugging PI3K in cancer: refining targets and therapeutic strategies

Yap, T. A., Bjerke, L. M., Clarke, P. A., & Workman, P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.016 · Cited by 206

PI3K inhibitors: review and new strategies

Zhang, M., Jang, H., & Nussinov, R. (2020) · Chemical Science · doi:10.1039/d0sc01676d · Cited by 184

mTOR signaling in tumorigenesis

Xu, K. L., Liu, P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.10.007 · Cited by 167

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Dolly, S. O., Wagner, A. J., Bendell, J. C., Kindler, H. L., Krug, L. M., Seiwert, T. Y., Zauderer, M. G., Lolkema, M. P., Apt, D., Yeh, R.-F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2225 · Cited by 142

Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs

Gerdes, H., Casado, P., Dokal, A. D., Hijazi, M., Akhtar, N., Osuntola, R., Rajeeve, V., Fitzgibbon, J., Travers, J., Britton, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22170-8 · Cited by 137

Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance

Masui, K., Tanaka, K., Ikegami, S., Villa, G. R., Yang, H., Yong, W. H., Cloughesy, T. F., Yamagata, K., Arai, N., Cavenee, W. K., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511759112 · Cited by 123

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Fusco, N., Malapelle, U., Fassan, M., Marchiò, C., Buglioni, S., Zupo, S., Criscitiello, C., Vigneri, P. G., Tos, A. P. D., Maiorano, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644737 · Cited by 124

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate

Stevens, M. M., Maire, C. L., Chou, N., Murakami, M. A., Knoff, D. S., Kikuchi, Y., Kimmerling, R. J., Liu, H., Haidar, S., Calistri, N. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3697 · Cited by 106

Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers

Fruman, D. A., & Cantley, L. C. (2014) · New England Journal of Medicine · doi:10.1056/nejme1400055 · Cited by 98

MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling

Wang, W., Shen, T., Dong, B., Creighton, C. J., Meng, Y., Zhou, W., Shi, Q., Zhou, H., Zhang, Y., Moore, D. D., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97712 · Cited by 95

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

Brun, S., Bestion, E., Raymond, É., Bassissi, F., Jílková, Z. M., Mezouar, S., Rachid, M., Novello, M., Tracz, J., Hamaï, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1988357 · Cited by 94

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer

Donnella, H. J., Webber, J. T., Levin, R. S., Camarda, R., Momcilovic, O., Bayani, N., Shah, K. N., Korkola, J. E., Shokat, K. M., Goga, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0081-9 · Cited by 90

Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities

Li, T., & Wang, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018856 · Cited by 86

G protein-coupled receptors (GPCRs) That Signal via Protein Kinase A (PKA) Cross-talk at Insulin Receptor Substrate 1 (IRS1) to Activate the phosphatidylinositol 3-kinase (PI3K)/AKT Pathway

Law, N. C., White, M. F., & Hunzicker-Dunn, M. E. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.763235 · Cited by 82

Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations

Yang, W., Raufi, A. G., & Klempner, S. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.003 · Cited by 78

Translational and clinical implications of the genetic landscape of prostate cancer

Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 78

Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants

Çört, A., Özben, T., Saso, L., Luca, C. D., & Korkina, L. G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4251912 · Cited by 78

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

Schafer, J. M., Lehmann, B. D., Ericsson, P. I. G., Marshall, C. B., Beeler, J. S., Redman, L. N., Jin, H., Sanchez, V. M., Stubbs, M. C., Scherle, P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8275 · Cited by 69

A genome-wide single nucleotide polymorphism and copy number variation analysis for number of piglets born alive

Stafuzza, N. B., Silva, R. M. D. O., Fragomeni, B. D. O., Masuda, Y., Huang, Y., Gray, K. A., & Lourenco, D. A. L. (2019) · BMC Genomics · doi:10.1186/s12864-019-5687-0 · Cited by 70

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

Kim, S. T., Kim, S., Klempner, S. J., Yoon, J. Y., Kim, N., Ahn, S., Bang, H., Kim, K., Park, W., Park, S. H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw669 · Cited by 68

The role of mTOR in age-related diseases

Chrienová, Ž., Nepovimová, E., & Kuča, K. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1955873 · Cited by 72

Empirical inference of circuitry and plasticity in a kinase signaling network

Wilkes, E. H., Terfve, C., Gribben, J. G., Sáez-Rodríguez, J., & Cutillas, P. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423344112 · Cited by 67

Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis

Bertacchini, J., Guida, M., Accordi, B., Mediani, L., Martelli, A. M., Barozzi, P., Petricoin, E. F., Liotta, L. A., Milani, G., Giordan, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.123 · Cited by 69

Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation

Cairns, J., Fridley, B. L., Jenkins, G. D., Zhuang, Y., Yu, J., & Wang, L. (2018) · EMBO Reports · doi:10.15252/embr.201744767 · Cited by 65

Cross-talk between the CK2 and AKT signaling pathways in cancer

Ruzzene, M., Bertacchini, J., Toker, A., & Marmiroli, S. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.03.002 · Cited by 61

Metabolism of Proliferating CellsPreprint

Chandel, N. S. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a040618 · Cited by 67

Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects

Qureshi, R., Zou, B., Alam, T., Wu, J., Lee, V. H.-F., & Yan, H. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3141697 · Cited by 61

MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT

Shen, T., Wang, W., Zhou, W., Coleman, I. M., Cai, Q., Dong, B., Ittmann, M., Creighton, C. J., Bian, Y., Meng, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135465 · Cited by 59

FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance

Bartel, C. A., Parameswaran, N., Cipriano, R., & Jackson, M. W. (2016) · Oncotarget · doi:10.18632/oncotarget.9544 · Cited by 57

TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer

Agarwal, N., Rinaldetti, S. L., Cheikh, B. B., Zhou, Q., Hass, E. P., Jones, R. T., Joshi, M., LaBarbera, D. V., Knott, S., Cech, T. R., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102423118 · Cited by 58

Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer

Boonyaratanakornkit, V., Hamilton, N. M., Márquez‐Garbán, D. C., Pateetin, P., McGowan, E. M., & Pietras, R. J. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.11.010 · Cited by 52

Pharmacogenomics of Scopoletin in Tumor Cells

Seo, E., Saeed, M. E. M., Law, B. Y. K., Wu, A., Kadioglu, O., Greten, H. J., & Efferth, T. (2016) · Molecules · doi:10.3390/molecules21040496 · Cited by 51

MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Dey, N., Leyland-Jones, B. R., & De, P. K. (2015) · Europe PMC (PubMed Central) · Cited by 50

Pentraxin-3 is a PI3K signaling target that promotes stem cell–like traits in basal-like breast cancers

Thomas, C., Henry, W. S., Cuiffo, B., Collmann, A. Y., Marangoni, E., Benhamo, V., Bhasin, M., Fan, C., Fuhrmann, L., Baldwin, A. S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aah4674 · Cited by 52

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications

Martínez‐Ciarpaglini, C., Fleitas, T., Gambardella, V., Llorca, M., Mongort, C., Mengual, R., Nieto, G., Navarro, L., Huerta, M., Roselló, S., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000470 · Cited by 49

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers

Packer, L., Geng, X., Bonazzi, V., Ju, R. J., Mahon, C. E., Cummings, M. C., Stephenson, S., & Pollock, P. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0415 · Cited by 45

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors

Echeverry, N., Ziltener, G., Barbone, D., Weder, W., Stahel, R. A., Broaddus, V. C., & Felley‐Bosco, E. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.124 · Cited by 48

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds

Carrella, D., Manni, I., Tumaini, B., Dattilo, R., Papaccio, F., Mutarelli, M., Sirci, F., Amoreo, C. A., Mottolese, M., Iezzi, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11318 · Cited by 48

Emerging molecular classifications and therapeutic implications for gastric cancer

Chen, T., Xu, X., & Zhou, P. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0111-5 · Cited by 47

miR-100-5p Downregulates mTOR to Suppress the Proliferation, Migration, and Invasion of Prostate Cancer Cells

Li, S.-L., Ye, Y., & Wang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578948 · Cited by 43

Role of phosphoproteomics in the development of personalized cancer therapies

Cutillas, P. R. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400104 · Cited by 42

Rapid, Multiplexed Phosphoprotein Profiling Using Silicon Photonic Sensor Arrays

Wade, J. H., Alsop, A. T., Vertin, N. R., Yang, H. W., Johnson, M. D., & Bailey, R. C. (2015) · ACS Central Science · doi:10.1021/acscentsci.5b00250 · Cited by 44

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R

de Lint, K., Poell, J. B., Soueidan, H., Jastrzebski, K., Rodriguez, J. V., Lieftink, C., Wessels, L. F. A., & Beijersbergen, R. L. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0865 · Cited by 42

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy

Sathe, A., Guerth, F. M., Cronauer, M. V., Heck, M. M., Thalgott, M. K., Gschwend, J. E., Retz, M. M., & Nawroth, R. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.534 · Cited by 39

Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer

Waugh, M. G. (2014) · Journal of Cancer · doi:10.7150/jca.9794 · Cited by 37

An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors

Wu, D., Yan, Y., Wei, T., Ye, Z., Xiao, Y., Pan, Y., Orme, J. J., Wang, D., Wang, L., Ren, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108744 · Cited by 37

mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy

Pazhooh, R. D., Farnood, P. R., Asemi, Z., Mirsafaei, L., Yousefi, B., & Mirzaei, H. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103142 · Cited by 36

Principles of dormancy evident in high-grade serous ovarian cancer

Shepherd, T. G., & Dick, F. A. (2022) · Cell Division · doi:10.1186/s13008-022-00079-y · Cited by 37

Small molecule targeting of SHIP1 and SHIP2

Kerr, W. G., Pedicone, C., Dormann, S., Pacherille, A., & Chisholm, J. D. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190775 · Cited by 38

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma

Ross, R. L., McPherson, H. R., Kettlewell, L., Shnyder, S. D., Hurst, C. D., Alder, O., & Knowles, M. A. (2016) · BMC Cancer · doi:10.1186/s12885-016-2570-0 · Cited by 35

ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma

Yun, M. R., Choi, H., Kang, H., Lee, Y., Joo, H., Kim, D. H., Kim, H. R., Hong, M. H., Yoon, S. O., & Cho, B. C. (2017) · Oncogene · doi:10.1038/onc.2017.339 · Cited by 35

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers

Harding, J. J., Awada, A. H., Roth, G. S., Decaens, T., Merle, P., Kotecki, N., Dreyer, C., Ansaldi, C., Rachid, M., Mezouar, S., et al. (2022) · Liver Cancer · doi:10.1159/000522418 · Cited by 34

Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection

Labots, M., van der Mijn, J. C., Beekhof, R., Piersma, S. R., Haas, R. R. D. G., Pham, T. V., Knol, J. C., Dekker, H., van Grieken, N. C. T., Verheul, H. M. W., et al. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.04.014 · Cited by 34

Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas

Janus, J. M., O’Shaughnessy, R. F. L., Harwood, C. A., & Maffucci, T. (2017) · Cancers · doi:10.3390/cancers9070086 · Cited by 34

Pharmacogenomic Characterization of Cytotoxic Compounds from Salvia officinalis in Cancer Cells

Kadioglu, O., & Efferth, T. (2015) · Journal of Natural Products · doi:10.1021/np501007n · Cited by 32

Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells

Nicastri, M. C., Rebecca, V. W., Amaravadi, R. K., & Winkler, J. D. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1395504 · Cited by 29

Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?

Tran, P. N., Nguyen, C., & Klempner, S. J. (2016) · International Neurourology Journal · doi:10.5213/inj.1632740.370 · Cited by 29

Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice

Chen, R., Zhao, Y., Huang, Y., Yang, Q., Zeng, X., Jiang, W., Liu, J., Thrasher, J. B., Forrest, M. L., & Li, B. (2015) · The Prostate · doi:10.1002/pros.22941 · Cited by 28

Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion

Mavrommati, I., Cisse, O., Falasca, M., & Maffucci, T. (2016) · Scientific Reports · doi:10.1038/srep23277 · Cited by 28

Synergistic interactions with PI3K inhibition that induce apoptosis

Zwang, Y., Jonas, O. H., Chen, C., Rinne, M. L., Doench, J. G., Piccioni, F., Tan, L., Huang, H., Wang, J., Ham, Y. J., et al. (2017) · eLife · doi:10.7554/elife.24523 · Cited by 28

A comprehensive review of stroke-related signaling pathways and treatment in western medicine and traditional Chinese medicine

Chen, B., & Jin, W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1200061 · Cited by 29

Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma

Vallejo-Díaz, J., Olazabal-Morán, M., Cariaga-Martínez, A. E., Pajares, M. J., Flores, J. M., Pı́o, R., Montuenga, L. M., & Carrera, A. C. (2016) · Oncotarget · doi:10.18632/oncotarget.13195 · Cited by 27

Predictive biomarkers along gastric cancer pathogenetic pathways

Panarese, I., Vita, F. D., Ronchi, A., Romano, M., Alfano, R., Martino, N. D., Marino, F. Z., Ferraraccio, F., & Franco, R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1301207 · Cited by 27

mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme

Ramaiah, M. J., & Kurappalli, R. K. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06462-2 · Cited by 29

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235

Xie, C., Freeman, M. J., Lu, H., Wang, X., Forster, C. L., Sarver, A. L., & Hallstrom, T. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16970 · Cited by 27

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition

McNeill, R. S., Stroobant, E. E., Smithberger, E., Canoutas, D. A., Butler, M. K., Shelton, A., Patel, S. D., Limas, J. C., Skinner, K., Bash, R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200014 · Cited by 25

Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines

Holzhauser, S., Lukoseviciute, M., Papachristofi, C., Vasilopoulou, C., Herold, N., Wickström, M., Kostopoulou, O. N., & Dalianis, T. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5167 · Cited by 24

Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases – potentially novel therapeutic targets

Ito, Y., Hart, J. R., & Vogt, P. K. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1522302 · Cited by 22

Targeted therapies in hepatocellular carcinoma: past, present, and future

Gujarathi, R., Franses, J. W., Pillai, A., & Liao, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1432423 · Cited by 22

A review of non-classical MAPK family member, MAPK4: A pivotal player in cancer development and therapeutic intervention

Yan, Y., Dai, T., Guo, M., Zhao, X., Chen, C., Zhou, Y., Qin, M., Xu, L., & Zhao, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132686 · Cited by 21

The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors

Rogers, H. A., Estranero, J. G., Gudka, K., & Grundy, R. G. (2016) · Oncotarget · doi:10.18632/oncotarget.13781 · Cited by 21

Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3–amplified lung adenocarcinoma cells

Shi, L., Tan, X., Liu, X., Jiang, Y. L., Bota‐Rabassedas, N., Niu, Y., Luo, J., Xi, Y., Zong, C. C., Creighton, C. J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023537118 · Cited by 20

Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes

Jillson, L. K., Yette, G. A., Laajala, T. D., Tilley, W. D., Costello, J. C., & Cramer, S. D. (2021) · Cancers · doi:10.3390/cancers13133272 · Cited by 20

Identifying therapeutic targets in gastric cancer: the current status and future direction

Yu, B., & Xie, J. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv084 · Cited by 19

Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines

Kostopoulou, O. N., Holzhauser, S., Lange, B. K. A., Ohmayer, A., Andonova, T., Bersani, C., Wickström, M., & Dalianis, T. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4896 · Cited by 19

Circular RNA profiling in plasma exosomes from patients with gastric cancer

Rao, M., Zhu, Y., Qi, L., Hu, F., & Gao, P. (2020) · Oncology Letters · doi:10.3892/ol.2020.11800 · Cited by 19

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth

Morrison, M. M., Williams, M. M., Vaught, D., Hicks, D. J., Lim, J., McKernan, C., Aurisicchio, L., Ciliberto, G., Simion, C., Sweeney, C. A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.169 · Cited by 18

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms

Pandey, R., & Kapur, R. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0388-z · Cited by 18

Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44

Malik, N., Nirujogi, R. S., Peltier, J., Macartney, T., Wightman, M., Prescott, A. R., Gourlay, R., Trost, M., Alessi, D. R., & Karapetsas, A. (2019) · Biochemical Journal · doi:10.1042/bcj20190608 · Cited by 18

New insights from the widening homogeneity perspective to target intratumor heterogeneity

Tong, M., Deng, Z., Zhang, X., He, B., Yang, M., Cheng, W., & Liu, Q. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0287-y · Cited by 17

Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment

Pedicona, F., Casado, P., Hijazi, M., Gribben, J. G., Rouault‐Pierre, K., & Cutillas, P. R. (2022) · Science Signaling · doi:10.1126/scisignal.abl7989 · Cited by 17

Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a Gβγ-dependent regulator of PI3Kγ enzymatic activity

Shymanets, A., Prajwal, P., Vadas, O., Czupalla, C., LoPiccolo, J., Brenowitz, M. D., Ghigo, A., Hirsch, E., Krause, E., Wetzker, R., et al. (2015) · Biochemical Journal · doi:10.1042/bj20150099 · Cited by 17

Lipid phosphatases SKIP and SHIP 2 regulate fibronectin‐dependent cell migration in glioblastoma

Ramos, A. R., Ghosh, S., Dedobbeleer, M., Robe, P. A. J. T., Rogister, B., & Erneux, C. (2019) · FEBS Journal · doi:10.1111/febs.14769 · Cited by 17

Advances in Palmitoylation: A key Regulator of liver cancer development and therapeutic targets

Zhu, Z., Feng, S., Zeng, A., & Song, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116810 · Cited by 15

Protein functional effector sncRNAs (pfeRNAs) in lung cancer

Brock, M. V., & Mei, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.013 · Cited by 15

Synergistic induction of cell death in haematological malignancies by combined phosphoinositide‐3‐kinase and BET bromodomain inhibition

Tinsley, S., Meja, K. K., Shepherd, C., & Khwaja, A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13283 · Cited by 15

Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features

Kim, H. J., & Kim, D. (2020) · Molecules · doi:10.3390/molecules25204641 · Cited by 17

eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors

Hijazi, M., Casado, P., Akhtar, N., Álvarez–Teijeiro, S., Rajeeve, V., & Cutillas, P. R. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100240 · Cited by 14

Preventive Effect of Combined Zingiber officinale and Terminalia chebula against DMBA-Induced Breast Cancer Rats via mTOR Inhibition

Mathiyazhagan, J., Ramamoorthy, S., Jayaraj, R., Madhyastha, H., & Muthukaliannan, G. K. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1903948 · Cited by 14

Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors

Muranen, T. E., Meric‐Bernstam, F., & Mills, G. B. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.020 · Cited by 14

Phosphorylation, Signaling, and Cancer: Targets and Targeting

Marmiroli, S., Fabbro, D., Miyata, Y., Pierobon, M., & Ruzzene, M. (2015) · BioMed Research International · doi:10.1155/2015/601543 · Cited by 14

E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing

Millán‐Uclés, Á., Zuluaga, S., Marqués, M., Vallejo-Díaz, J., Sanz, L., Cariaga-Martínez, A. E., Real, F. X., & Carrera, A. C. (2016) · Oncotarget · doi:10.18632/oncotarget.13414 · Cited by 13

MINI REVIEW What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the

Pathway, P. K., Klempner, S. J., Myers, A. P., & Cantley, L. C. (2016)

Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance

Paddock, M. N., Field, S. J., & Cantley, L. C. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s092130 · Cited by 24

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,581

The phosphoinositide 3-kinase pathway and therapy resistance in cancer

Brown, K., & Toker, A. (2015) · F1000Prime Reports · doi:10.12703/p7-13 · Cited by 115

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 31